Form 4: Beam Therapeutics CEO Sells Shares for Tax Withholding

Beam Therapeutics CEO John M. Evans reports a sale of common stock to cover tax obligations upon vesting of restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• John M. Evans, CEO of Beam Therapeutics Inc. (BEAM), reported a transaction on April 1, 2026.
• This transaction involved the sale of 30,078 shares of common stock at a price of $24.58 per share.
• The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
• These units were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on March 31st of 2022, 2023, 2024, and 2025.
• The sales were executed as part of a Rule 10b5-1 trading plan established by Mr. Evans on May 19, 2023.
• Following this transaction, Mr. Evans beneficially owns 1,047,205 shares of common stock directly.
• Additionally, 103,000 shares are held indirectly by the John M. Evans, III 2018 Irrevocable Trust.
• The filing also notes the acquisition of 616 shares by Mr. Evans under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a stock sale by the CEO, it is a routine transaction for tax withholding under a pre-arranged plan, not indicative of a negative outlook on the company's performance.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and non-opportunistic approach to managing equity.
• The transaction was for tax withholding purposes, a common and expected event for executives upon vesting of equity awards.
• Mr. Evans continues to hold a significant number of shares (1,047,205 directly) after the transaction, demonstrating continued beneficial ownership.

Negatives

• A portion of the CEO's equity was sold, which could be perceived negatively by some investors, although it was for tax purposes.
• The sale price of $24.58 per share may be lower than current market prices, depending on the trading day.

Risks

• The Rule 10b5-1 trading plan, while providing a defense against insider trading allegations, still involves the disposition of company stock by a key executive.
• Future vesting events and associated tax obligations could lead to further sales of stock by the reporting person.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on a past transaction.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
• These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Beam Therapeutics' CEO is a common practice among executives to manage equity sales in a compliant manner, particularly for covering tax liabilities arising from equity compensation, which is prevalent in the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale is for tax purposes and executed under a 10b5-1 plan, minimizing concerns about insider selling based on non-public information. However, any sale of stock by a CEO can be subject to interpretation.
• Employees: The transaction is related to executive compensation and tax obligations, with no direct impact on other employees.
• Creditors: No direct impact on creditors.
• Suppliers/Customers: No direct impact.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for future vesting events.
• Monitoring of future equity vesting and potential tax withholding transactions by the reporting person.

Key Dates

Keywords

Form 4, SEC Filing, Beam Therapeutics, BEAM, Insider Transaction, Stock Sale, John M. Evans, CEO, Restricted Stock Units, Vesting, Tax Withholding, Rule 10b5-1, Beneficial Ownership, Equity Incentive Plan, Employee Stock Purchase Plan